Premature Birth Drug Has No Benefit, But Serious Side Effect

Premature Birth Drug Has No Benefit, But Serious Side Effect

A drug that is used by pregnant women to prevent preterm birth may not only not be effective, but may increase the risk of a serious side effect, gestational diabetes.

The drug, Makena, is a synthetic progesterone known as 17-alpha hydroxyprogesterone caproate. It was approved by the FDA in 2011 to treat women at risk of delivering a second premature baby. The drug received accelerated approval in large part to a 2003 study published in the new England Journal of Medicine.

Makena is also endorsed American College of Obstetricians and Gynecologists and the Society for Maternal-Fetal Medicine. However, the drug has been plagued by controversy due to its relatively high price tag and questions surrounding the 2003 study.

In the new study, researchers offered the drug to women if they had a history of premature births and were carrying a single fetus. The study followed a total of 430 women who took the drug at a Texas hospital. Those results were compared with the premature birth rate of 5,787 women at the same hospital who had a history of premature delivery but didn’t take the drug.

Premature birth occurred in 25% of the women that took Makena, compared to a 16.8% in women who never took the drug, researchers reported in the American Journal of Obstetrics and Gynecology. And the rate of gestational diabetes was 13.4% in women treated with Makena, compared with 8% in the historical group.

While gestational diabetes often goes away after birth, it can lead to the delivery of larger babies and higher chances for cesarean sections and other birth complications.


Jonathan Block

Jonathan Block

Jonathan Block is an associate editor at BioCentury, which provides news and information about the biotechnology and pharmaceutical industries. Prior to joining BioCentury in 2019, Jonathan worked for MedShadow as content editor. He has been an editor and writer for multiple pharmaceutical, health and medical publications, including The Pink Sheet, Modern Healthcare, Health Plan Week and Psychiatry Advisor. He holds a BA from Tufts University and is earning an MPH with a focus on health policy from the CUNY Graduate School of Public Health & Health Policy.


Did you find this article helpful?


Latest News

Breaking News – EpiPen Malfunction

Breaking News – EpiPen Malfunction

Just released from the FDA – Pfizer has informed the FDA that they are aware of several continuing problems that people are having using the EpiPen (epinephrine) and EpiPen Jr (epinephrine) auto-injectors and generic versions. Some of the problems are from user error and some from EpiPen malfunction. Here are…

ACE Inhibitors in the Time of Coronavirus

ACE Inhibitors in the Time of Coronavirus

Are you worried about ACE inhibitors and coronavirus? You may be hearing that one of the entry methods for the coronavirus in humans is by attaching to the ACE-2 enzyme. This has raised alarms among those with heart disease who use ACE inhibitors (with names ending in -pril, such as…

  • Advertisement